BRPI1009576A2 - anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente. - Google Patents

anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.

Info

Publication number: BRPI1009576A2
Authority: BR; Brazil
Prior art keywords: antibody; cloning; patient; treating; producing
Prior art date: 2009-03-11

Application number

BRPI1009576A

Other languages

English (en)

Inventor

Alastair David Griffiths Lawson

Bryan John Smith

Daniel John Lightwood

Kerry Louise Tyson

Neil Gozzard

Roger Thomas Palframan

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-11

Filing date

2010-03-10

Publication date

2016-03-08

2010-03-10 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2016-03-08 Publication of BRPI1009576A2 publication Critical patent/BRPI1009576A2/pt

2020-04-07 Publication of BRPI1009576B1 publication Critical patent/BRPI1009576B1/pt

2021-05-25 Publication of BRPI1009576B8 publication Critical patent/BRPI1009576B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dispersion Chemistry (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI1009576A 2009-03-11 2010-03-10 anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13. BRPI1009576B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0904214.4A GB0904214D0 (en)	2009-03-11	2009-03-11	Biological products
PCT/GB2010/000432 WO2010103274A1 (en)	2009-03-11	2010-03-10	Antibody molecules having binding specificity for human il-13

Publications (3)

Publication Number	Publication Date
BRPI1009576A2 true BRPI1009576A2 (pt)	2016-03-08
BRPI1009576B1 BRPI1009576B1 (pt)	2020-04-07
BRPI1009576B8 BRPI1009576B8 (pt)	2021-05-25

Family

ID=40600884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009576A BRPI1009576B8 (pt)	2009-03-11	2010-03-10	anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13.

Country Status (27)

Country	Link
US (3)	US8691233B2 (pt)
EP (2)	EP3168235A1 (pt)
JP (2)	JP5836130B2 (pt)
KR (1)	KR101773505B1 (pt)
CN (1)	CN102388066B (pt)
AR (1)	AR075849A1 (pt)
AU (1)	AU2010222693B2 (pt)
BR (1)	BRPI1009576B8 (pt)
CA (1)	CA2754539C (pt)
CY (1)	CY1118640T1 (pt)
DK (1)	DK2406283T3 (pt)
EA (1)	EA032222B1 (pt)
ES (1)	ES2615978T3 (pt)
GB (1)	GB0904214D0 (pt)
HR (1)	HRP20170234T1 (pt)
HU (1)	HUE031923T2 (pt)
IL (1)	IL215014A (pt)
LT (1)	LT2406283T (pt)
ME (1)	ME02607B (pt)
MX (1)	MX2011009390A (pt)
PL (1)	PL2406283T3 (pt)
PT (1)	PT2406283T (pt)
RS (1)	RS55734B1 (pt)
SI (1)	SI2406283T1 (pt)
TW (1)	TWI476004B (pt)
UY (1)	UY32489A (pt)
WO (1)	WO2010103274A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0904214D0 (en) *	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
US20160272706A1 (en) *	2015-01-12	2016-09-22	Medimmune Limited	Il-13 binding proteins and uses thereof
EA202190162A3 (ru)	2016-04-27	2021-11-30	Эббви Инк.	Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
WO2018078186A1 (en)	2016-10-31	2018-05-03	Vectura Limited	Inhalable powder composition comprising il-13 antibody
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN109776677B (zh) *	2017-11-15	2023-11-03	尚华科创投资管理（江苏）有限公司	一种人源化抗il-13抗体及其制备方法和应用
EP3735427A4 (en) *	2018-01-05	2021-09-15	Immunext Inc.	ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
MA55204A (fr)	2019-03-06	2022-01-12	Regeneron Pharma	Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
MA55372A (fr)	2019-03-21	2022-01-26	Regeneron Pharma	Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
WO2021142217A1 (en) *	2020-01-10	2021-07-15	Dyne Thereapeutics, Inc.	Muscle targeting complexes and uses thereof for modulation of milck1
US20230111147A1 (en) *	2020-01-10	2023-04-13	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
TW202216771A (zh) *	2020-06-26	2022-05-01	德商拜耳廠股份有限公司	用於治療應用之ccr8抗體
WO2023130010A1 (en)	2021-12-30	2023-07-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en) *	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0768377A1 (en)	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5750373A (en) *	1990-12-03	1998-05-12	Genentech, Inc.	Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
ES2107471T3 (es)	1990-08-06	1997-12-01	Eastman Chem Co	Mezclas polimeras de poliesteres y poliestireno para tintas acuosas.
DK0814159T3 (da)	1990-08-29	2005-10-24	Genpharm Int	Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
MD1652G2 (ro) *	1991-03-29	2001-12-31	Sanofi-Synthelabo	Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină
WO1992018619A1 (en)	1991-04-10	1992-10-29	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5596072A (en) *	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
JPH09506262A (ja)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	特異的抗体の製造方法
DK0744958T3 (da)	1994-01-31	2003-10-20	Univ Boston	Polyklonale antistofbiblioteker
FR2716640B1 (fr) *	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) *	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en) *	1996-03-01	2006-07-18	Genetics Institute, Llc	Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US6584343B1 (en) *	2000-03-15	2003-06-24	Resolution Medical, Inc.	Multi-electrode panel system for sensing electrical activity of the heart
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20040234499A1 (en)	2001-10-26	2004-11-25	David Shealy	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003086457A2 (en)	2002-04-08	2003-10-23	The John P. Robarts Research Institute	Method of treating or preventing autoimmune disease
WO2004022096A1 (en)	2002-09-06	2004-03-18	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) *	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1570267B1 (en)	2002-12-03	2011-10-12	UCB Pharma, S.A.	Assay for identifying antibody producing cells
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
CA2527020A1 (en)	2003-07-01	2005-01-13	Celltech R & D Limited	Modified antibody fab fragments
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
EP1703893B1 (en)	2003-12-23	2012-04-11	Genentech, Inc.	Novel anti-il 13 antibodies and uses thereof
ES2432112T3 (es) *	2004-02-10	2013-11-29	The Regents Of The University Of Colorado, A Body Corporate	Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
WO2005079755A2 (en)	2004-02-12	2005-09-01	Nektar Therapeutics	Interleukin-13 antagonist powders, spray-dried particles, and methods
CA2557724A1 (en)	2004-02-27	2005-10-06	Centocor, Inc.	Methods and compositions for treating il-13 related pathologies
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US20070048785A1 (en)	2004-06-09	2007-03-01	Lin Laura L	Anti-IL-13 antibodies and complexes
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
AU2005307831A1 (en) *	2004-11-17	2006-05-26	Amgen, Inc.	Fully human monoclonal antibodies to IL-13
EP1669394A1 (en)	2004-12-10	2006-06-14	The Procter & Gamble Company	Superabsorbent polymer particles with improved surface cross-linking and hydrophilicity and method of making them
WO2006124451A2 (en)	2005-05-11	2006-11-23	Centocor, Inc.	Anti-il-13 antibodies, compositions, methods and uses
GB0513852D0 (en)	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
GB2430883B (en)	2005-09-30	2008-03-19	Cambridge Antibody Tech	Interleukin-13 antibody composition
KR20130020850A (ko)	2005-10-21	2013-02-28	노파르티스 아게	Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
JP2009525267A (ja)	2006-01-11	2009-07-09	アエロヴァンスインコーポレイティッド	ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
GB0600488D0 (en)	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
CN101512008B (zh)	2006-09-08	2015-04-01	艾伯维巴哈马有限公司	白介素-13结合蛋白
JP2010512402A (ja)	2006-12-11	2010-04-22	ワイスエルエルシー	Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法
BRPI0806313A2 (pt) *	2007-01-09	2011-09-06	Wyeth Corp	Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
WO2008086043A2 (en)	2007-01-10	2008-07-17	Wyeth	Methods and compositions for assessment and treatment of asthma
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
AU2008328726B2 (en) *	2007-11-30	2014-06-12	Glaxo Group Limited	Antigen-binding constructs
US8399630B2 (en) *	2008-08-20	2013-03-19	Centocor Ortho Biotech Inc.	Engineered anti-IL-13 antibodies, compositions, methods and uses
GB0904214D0 (en) *	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products

2009
- 2009-03-11 GB GBGB0904214.4A patent/GB0904214D0/en not_active Ceased
2010
- 2010-03-09 TW TW099106694A patent/TWI476004B/zh active
- 2010-03-10 LT LTEP10714046.9T patent/LT2406283T/lt unknown
- 2010-03-10 KR KR1020117023891A patent/KR101773505B1/ko active IP Right Grant
- 2010-03-10 HU HUE10714046A patent/HUE031923T2/en unknown
- 2010-03-10 AU AU2010222693A patent/AU2010222693B2/en active Active
- 2010-03-10 CA CA2754539A patent/CA2754539C/en active Active
- 2010-03-10 SI SI201031399A patent/SI2406283T1/sl unknown
- 2010-03-10 ES ES10714046.9T patent/ES2615978T3/es active Active
- 2010-03-10 US US12/720,804 patent/US8691233B2/en active Active
- 2010-03-10 PL PL10714046T patent/PL2406283T3/pl unknown
- 2010-03-10 AR ARP100100720A patent/AR075849A1/es active IP Right Grant
- 2010-03-10 DK DK10714046.9T patent/DK2406283T3/en active
- 2010-03-10 CN CN201080014682.1A patent/CN102388066B/zh active Active
- 2010-03-10 PT PT107140469T patent/PT2406283T/pt unknown
- 2010-03-10 ME MEP-2017-38A patent/ME02607B/me unknown
- 2010-03-10 WO PCT/GB2010/000432 patent/WO2010103274A1/en active Application Filing
- 2010-03-10 BR BRPI1009576A patent/BRPI1009576B8/pt active IP Right Grant
- 2010-03-10 EP EP16198084.2A patent/EP3168235A1/en not_active Withdrawn
- 2010-03-10 EP EP10714046.9A patent/EP2406283B1/en active Active
- 2010-03-10 JP JP2011553509A patent/JP5836130B2/ja active Active
- 2010-03-10 MX MX2011009390A patent/MX2011009390A/es active IP Right Grant
- 2010-03-10 RS RS20170163A patent/RS55734B1/sr unknown
- 2010-03-10 EA EA201101303A patent/EA032222B1/ru not_active IP Right Cessation
- 2010-03-11 UY UY0001032489A patent/UY32489A/es not_active Application Discontinuation
2011
- 2011-09-07 IL IL215014A patent/IL215014A/en active IP Right Grant
2014
- 2014-02-21 US US14/186,074 patent/US9394361B2/en active Active
2015
- 2015-07-31 JP JP2015151879A patent/JP2016025856A/ja active Pending
2016
- 2016-06-13 US US15/180,916 patent/US9957320B2/en active Active
2017
- 2017-02-13 HR HRP20170234TT patent/HRP20170234T1/hr unknown
- 2017-02-16 CY CY20171100215T patent/CY1118640T1/el unknown

Also Published As

Publication number	Publication date
JP5836130B2 (ja)	2015-12-24
US9394361B2 (en)	2016-07-19
JP2012520067A (ja)	2012-09-06
WO2010103274A1 (en)	2010-09-16
IL215014A (en)	2016-07-31
MX2011009390A (es)	2011-10-11
KR101773505B1 (ko)	2017-08-31
US9957320B2 (en)	2018-05-01
KR20110128922A (ko)	2011-11-30
US20140178387A1 (en)	2014-06-26
DK2406283T3 (en)	2017-02-27
PL2406283T3 (pl)	2017-05-31
AU2010222693A1 (en)	2011-09-29
BRPI1009576B8 (pt)	2021-05-25
HUE031923T2 (en)	2017-08-28
LT2406283T (lt)	2017-02-27
US20100260773A1 (en)	2010-10-14
TW201036636A (en)	2010-10-16
CY1118640T1 (el)	2017-07-12
US20160289323A1 (en)	2016-10-06
SI2406283T1 (sl)	2017-03-31
TWI476004B (zh)	2015-03-11
PT2406283T (pt)	2017-02-21
CN102388066B (zh)	2015-04-01
EP2406283A1 (en)	2012-01-18
ME02607B (me)	2017-06-20
ES2615978T3 (es)	2017-06-09
EP3168235A1 (en)	2017-05-17
UY32489A (es)	2010-10-29
GB0904214D0 (en)	2009-04-22
RS55734B1 (sr)	2017-07-31
HRP20170234T1 (hr)	2017-04-07
CA2754539C (en)	2017-09-12
EA032222B1 (ru)	2019-04-30
IL215014A0 (en)	2011-11-30
US8691233B2 (en)	2014-04-08
EA201101303A1 (ru)	2012-05-30
BRPI1009576B1 (pt)	2020-04-07
AU2010222693B2 (en)	2014-12-04
AR075849A1 (es)	2011-05-04
CN102388066A (zh)	2012-03-21
JP2016025856A (ja)	2016-02-12
CA2754539A1 (en)	2010-09-16
EP2406283B1 (en)	2016-11-16

Publication	Publication Date	Title
BRPI1009576A2 (pt)	2016-03-08	anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.
BRPI0717768A2 (pt)	2013-11-05	Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BR112012004823A8 (pt)	2017-10-03	Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112014026990A2 (pt)	2017-07-11	anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI1008692B8 (pt)	2021-05-25	anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BRPI0619595B8 (pt)	2022-12-13	anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
BR112013015129A2 (pt)	2018-10-09	anticorpo isolado ou fragmento do mesmo, composição farmacêutica, método para imunização passiva, método para tratamento de uma infecção pelo vírus da dengue, método para produzir um anticorpo de neutralização contra um vírus da dengue, ácido nucleico isolado, vetor de expressão e célula hospedeira
BR112012002603A2 (pt)	2016-11-22	composição imunogênica, proteína de fusão, polinucleotídeo, vacina, processo para preparar a vacina, uso da composição imunogênica, e, método para tratar ou prevenir doença estafilocócica.
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BRPI0918555A2 (pt)	2016-05-03	anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012015255A2 (pt)	2017-01-10	"anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
BRPI0807269A2 (pt)	2014-04-29	"anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos"
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BR112017009728A2 (pt)	2018-02-06	anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
BR112014000627A2 (pt)	2018-04-17	polipepitídeo da polimerase mitante, proteína de fusão, moécula de ácido nucleico, vetor, processo de produção do vetor, célula hospedeira, método, composição, uso e kit
IL212047A (en)	2016-03-31	Human-derived antibody linked to IgF-1 and IgF-2, a DNA encoded for this antibody, an expression vector containing this DNA molecule and a host cell containing the expression vector, a method for producing this antibody and a pharmaceutical preparation containing it for the treatment of irregularities
BRPI0819688A2 (pt)	2015-06-16	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
WO2013059524A3 (en)	2013-06-13	Antibodies directed against influenza
BR112014027166A2 (pt)	2017-06-27	anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-25	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-02-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-04-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF